iScience (Feb 2023)

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

  • Denisa Bojkova,
  • Philipp Reus,
  • Leona Panosch,
  • Marco Bechtel,
  • Tamara Rothenburger,
  • Joshua D. Kandler,
  • Annika Pfeiffer,
  • Julian U.G. Wagner,
  • Mariana Shumliakivska,
  • Stefanie Dimmeler,
  • Ruth Olmer,
  • Ulrich Martin,
  • Florian W.R. Vondran,
  • Tuna Toptan,
  • Florian Rothweiler,
  • Richard Zehner,
  • Holger F. Rabenau,
  • Karen L. Osman,
  • Steven T. Pullan,
  • Miles W. Carroll,
  • Richard Stack,
  • Sandra Ciesek,
  • Mark N. Wass,
  • Martin Michaelis,
  • Jindrich Cinatl, Jr.

Journal volume & issue
Vol. 26, no. 2
p. 105944

Abstract

Read online

Summary: Reliable, easy-to-handle phenotypic screening platforms are needed for the identification of anti-SARS-CoV-2 compounds. Here, we present caspase 3/7 activity as a readout for monitoring the replication of SARS-CoV-2 isolates from different variants, including a remdesivir-resistant strain, and of other coronaviruses in numerous cell culture models, independently of cytopathogenic effect formation. Compared to other models, the Caco-2 subline Caco-2-F03 displayed superior performance. It possesses a stable SARS-CoV-2 susceptibility phenotype and does not produce false-positive hits due to drug-induced phospholipidosis. A proof-of-concept screen of 1,796 kinase inhibitors identified known and novel antiviral drug candidates including inhibitors of phosphoglycerate dehydrogenase (PHGDH), CDC like kinase 1 (CLK-1), and colony stimulating factor 1 receptor (CSF1R). The activity of the PHGDH inhibitor NCT-503 was further increased in combination with the hexokinase II (HK2) inhibitor 2-deoxy-D-glucose, which is in clinical development for COVID-19. In conclusion, caspase 3/7 activity detection in SARS-CoV-2-infected Caco-2-F03 cells provides a simple phenotypic high-throughput screening platform for SARS-CoV-2 drug candidates that reduces false-positive hits.

Keywords